

Voyageur Pharmaceuticals Ltd. Announces Issuance of Stock Options and Deferred Share Units

written by Igor Makarov | August 12, 2021

August 12, 2021 ([Source](#)) – Voyageur Pharmaceuticals Ltd. (TSXV:VM) USA (OTC:VYYRF) (the “Company” or “Voyageur”) announced that it has issued 200,000 options to directors pursuant to its incentive stock option plan (the “Options”). In addition, the Company announces it has issued 169,872 Deferred Share Units (“DSU’S”) to directors pursuant to its equity incentive compensation plan.

The grants referred to above are subject to approval of the TSX Venture Exchange (“TSXV”). The Company’s equity incentive compensation plan was adopted by the Company following receipt of approval by a majority of disinterested shareholders at the Company’s AGM held on June 23, 2021. The incentive stock option plan of the Company was also approved at this meeting.

About Voyageur

Voyageur Pharmaceuticals Ltd. is Canadian public company listed on the TSXV under the trading symbol VM. Voyageur is focused on the development of barite and iodine, Active Pharmaceutical Ingredient (API) minerals. The near-term focus is developing barium and iodine radio-contrast pharmaceutical products.

Voyageur’s goal is to initially generate the positive cash flow from operations using third party GMP pharmaceutical manufacturers in Canada and internationally. Ultimately, Voyageur has plans to build all the required infrastructure to

become 100% self-sufficient with all manufacturing. Voyageur owns a 100% interest in three barium sulfate (barite) projects including two properties suitable in grade for the industrial barite marketplace, with interests in a high-grade iodine, lithium & bromine brine project located in Utah, USA.

Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiology medical field, by controlling all primary input costs under the motto of: "From the Earth to the Bottle"

For Further Media Information or to set up an interview, please contact:

Brent Willis
President & CEO
E brent@vpharma.ca

Ron Love
CFO
T 403.818.6086
E ronl@vpharma.ca

Forward Looking Information

This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to receipt of TSXV approval for the grants described herein, as well as statements relating to the development of barium and iodine radio-contract pharmaceutical products, and statements relating to the Company's long term plans, including with respect to becoming 100% self-sufficient with all manufacturing.. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information

will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR website at www.sedar.com. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.

Reader Advisory

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES